KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Short term Debt: 2009-2023

Historic Short term Debt for Biomarin Pharmaceutical (BMRN) over the last 13 years, with Dec 2023 value amounting to $493.9 million.

  • Biomarin Pharmaceutical's Short term Debt was N/A to $494.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $494.8 million, marking a year-over-year change of. This contributed to the annual value of $493.9 million for FY2023, which is 3001.27% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Short term Debt stood at $493.9 million for FY2023, which was up 3,001.27% from $15.9 million recorded in FY2022.
  • Biomarin Pharmaceutical's Short term Debt's 5-year high stood at $493.9 million during FY2023, with a 5-year trough of $15.9 million in FY2022.
  • Over the past 3 years, Biomarin Pharmaceutical's median Short term Debt value was $48.2 million (recorded in 2021), while the average stood at $186.0 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Short term Debt slumped by 66.98% in 2022 and then soared by 3,001.27% in 2023.
  • Yearly analysis of 4 years shows Biomarin Pharmaceutical's Short term Debt stood at $361.9 million in 2019, then reached $48.2 million in 2021, then plummeted by 66.98% to $15.9 million in 2022, then soared by 3,001.27% to $493.9 million in 2023.